Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals today launched a new program to expand medication access and provide grant funding to free and charitable clinics that care for medically underserved patients suffering from depression and/or anxiety. Teva is providing free and charitable clinics with $2 million in grant funding over two years and making available, on a charitable basis, a portfolio of commonly used generic medications that treat depression and anxiety. The new pilot program – initially set in Florida, New Jersey and California – aims to advance access to mental health care for uninsured populations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005112/en/
"Access to mental health care is critical yet distributed unevenly across the U.S.," said Thomas Tighe, CEO and President of Direct Relief. "Direct Relief is joining NAFC and Teva Pharmaceuticals in supporting community-based facilities to extend mental health care for those most in need."
The COVID-19 pandemic exacerbated access to adequate health services and mental health care needs. The new initiative will help address mental health access through a two-pronged approach to care: medication donations and community grants for free and charitable clinics, to help address key equity issues and advance quality care for underserved populations.
Products will be available to free and charitable clinics and pharmacies in Direct Relief's network. NAFC will help identify and evaluate programs eligible for grants and facilitate a community of learning between grantee clinics.
"Free and Charitable Clinics are beacons in their communities where access to affordable prescription medications and flexible funding resources are obstacles faced every day," said Nicole Lamoureux, President and CEO of NAFC. "With this program, we hope to reduce barriers to care for underserved populations by working with grantees to identify innovative, scalable ideas and approaches that enhance mental and behavioral health care access, particularly as the pandemic continues to spotlight severe inequities in care."
Expanding Access and Delivering Care
Anxiety and depression disorders affect more than 40 million adults in the U.S. every year. Additionally, 84 percent of physicians reported an increase in new diagnoses of mental health conditions since the pandemic began, especially among racial and ethnic minorities and lower-income households, according to a recent nationwide survey by the Morehouse School of Medicine and Teva.
"As a company responsible for 1 in 12 generic prescriptions in the U.S. with our portfolio of accessible medicines, it is critical to our mission to help increase access to quality care," added Dr. Sven Dethlefs, Executive Vice President, North America Commercial, at Teva. "Through this partnership with Direct Relief and NAFC, we are committed to reducing the disparities in health care that are hindering health equity by uncovering novel solutions that improve the lives of patients, their families and their communities."
Teva's support for the U.S. Access program stems from its public commitment to launch eight global access programs by 2025. In 2020, the company's generic medicines directly saved U.S. patients an estimated $4.2 billion.
Grant Funding for Critical Facilities
As of today, Direct Relief will accept proposals from eligible free and charitable clinics and charitable pharmacies, who are members of the National Association of Free and Charitable Clinics, in California, Florida, and New Jersey. Specifically, Direct Relief seeks innovative programs that advance health equity for populations with high unmet needs, support patient education and outreach, service delivery, or point of care models to help promote access or reduce barriers to care. Proposals must address clinical or non-clinical interventions for treating depression and anxiety for populations, including racial and ethnic minorities and LGBTQIA+ individuals. Eligible clinics will be contacted directly by Direct Relief.
About Direct Relief
A humanitarian organization committed to improving the health and lives of people affected by poverty and emergencies, Direct Relief delivers lifesaving medical resources throughout the U.S. and world to communities in need—without regard to politics, religion, or ability to pay. For more information, visit https://www.DirectRelief.org.
About National Association of Free and Charitable Clinics
National Association of Free and Charitable Clinics (NAFC) is the only nonprofit 501c (3) organization whose mission is solely focused on the issues and needs of the medically underserved throughout the nation and the more than 1,400 Free and Charitable Clinics that serve them. The NAFC has earned the Platinum Seal of Transparency from GuideStar and a 4-star rating from Charity Navigator. Founded in 2001 and headquartered near Washington, D.C., the NAFC is working to ensure that the medically underserved have access to affordable quality health care and strives to be a national voice promoting quality health care for all. For more information about the NAFC, please visit www.nafcclinics.org.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on Teva’s management current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our social, economic, environment and governance related strategies and goals; our ability to satisfy the targets set forth in our sustainability-linked senior notes and in other sustainability-linked financing instruments that we may issue; and the impact of ESG issues on our business; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our substantial indebtedness; our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto, costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic, the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments, increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and compliance with anti-corruption sanctions and trade control laws; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Risk Factors” and “Forward-Looking Statements” and in our other reports that we file with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Source: Teva Pharmaceutical Industries Limited